Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

Dotinurad is a novel selective urate reabsorption inhibitor (SURI) which reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). This study was intended to verify the efficacy and safety of dotinurad following treatment for 34 or 58 weeks in hyperuricemic patients with or without gout.This long-term study had an open-label design with dose escalation. The dose of dotinurad started at 0.5 mg/day and was increased...